Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 See also  




2 References  













Tazomeline






●فارسی
 ●日本語
 ●Српски / srpski
 ●Srpskohrvatski / српскохрватски
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  



In other projects  


●Wikimedia Commons
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Tazomeline
Clinical data
ATC code
  • None
Identifiers

  • 5-[4-(hexylsulfanyl)-1,2,5-thiadiazol-3-yl]-1-methyl-1,2,3,6-tetrahydropyridine

CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H23N3S2
Molar mass297.48 g·mol−1
3D model (JSmol)

  • n2snc(/C1=C/CCN(C)C1)c2SCCCCCC

Tazomeline (LY-287,041) is a drug which acts as a non-selective muscarinic acetylcholine receptor agonist.[1][2] It was in clinical trials for the treatment of cognitive dysfunction such as that seen in Alzheimer's disease and schizophrenia, but development was apparently scrapped for unknown reasons.[1][2][3] Another of the patented uses is for the treatment of "severe painful conditions".

See also[edit]

References[edit]

  1. ^ a b Langmead CJ, Watson J, Reavill C (February 2008). "Muscarinic acetylcholine receptors as CNS drug targets". Pharmacology & Therapeutics. 117 (2): 232–43. doi:10.1016/j.pharmthera.2007.09.009. PMID 18082893.
  • ^ a b Amos D Korczyn (October 2000). "Muscarinic M1 Agonists in the Treatment of Alzheimer's Disease". Expert Opinion on Investigational Drugs. 9 (10): 2259–2267(9). doi:10.1517/13543784.9.10.2259. PMID 11060805. S2CID 32214700.
  • ^ Mashkovskii MD, Glushkov RG (April 2001). "Drugs for the Treatment of Alzheimer's Disease". Pharmaceutical Chemistry Journal. 35 (4): 179–182. doi:10.1023/A:1010474325601. S2CID 39866378.

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Tazomeline&oldid=1217263561"
    Categories: 
    ●Drugs not assigned an ATC code
     ●Muscarinic agonists
     ●Tetrahydropyridines
     ●Thiadiazoles
     ●Abandoned drugs
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Articles without InChI source
     ●Drugs with no legal status
     ●Articles containing unverified chemical infoboxes
      


    ●This page was last edited on 4 April 2024, at 19:58 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki